{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:57:50Z","timestamp":1791320270071,"version":"4.3.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T00:00:00Z","timestamp":1538697600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Pain Headache Rep"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s11916-018-0732-2","type":"journal-article","created":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T04:25:44Z","timestamp":1538713544000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Buprenorphine for Chronic Pain: a Systemic Review"],"prefix":"10.1007","volume":"22","author":[{"given":"Michael A.","family":"Fishman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,5]]},"reference":[{"key":"732_CR1","doi-asserted-by":"crossref","unstructured":"Institute of Medicine. Relieving Pain in America: a Blueprint for Transforming Prevention, Care, Education, and Research. Vol. 26, Journal of Pain & Palliative Care Pharmacotherapy. Washington, DC: The National Academies Press; 2012.","DOI":"10.3109\/15360288.2012.678473"},{"key":"732_CR2","unstructured":"Centers for Disease Control. Annual Surveillance Report Of Drug-related Risks And Outcomes [Internet]. 2017 [cited 2018 Apr 13]. Available from: https:\/\/www.cdc.gov\/drugoverdose\/pdf\/pubs\/2017-cdc-drug-surveillance-report.pdf"},{"key":"732_CR3","unstructured":"Centers for Disease Control. Prescription Opioid Overdose Data [Internet]. [cited 2018 Apr 13]. Available from: https:\/\/www.cdc.gov\/drugoverdose\/data\/overdose.html"},{"issue":"6","key":"732_CR4","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1093\/bja\/aen094","volume":"100","author":"KTS Pattinson","year":"2008","unstructured":"Pattinson KTS. Opioids and the control of respiration. Br J Anaesth Oxford University Press. 2008;100(6):747\u201358.","journal-title":"Br J Anaesth Oxford University Press"},{"key":"732_CR5","unstructured":"Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain\u2014United States, 2016.[Erratum appears in MMWR Recomm Rep. 2016;65(11):295]. Morb Mortal Wkly Report Recomm Reports. 2016;65(1):1\u201349."},{"issue":"5","key":"732_CR6","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/j.1533-2500.2010.00378.x","volume":"10","author":"J Pergolizzi","year":"2010","unstructured":"\u2022 Pergolizzi J, Aloisi AM, Dahan A, Filitz J, Langford R, Likar R, et al. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract. 2010;10(5):428\u201350 A rational look at the pharmacological properties of buprenorphine that addresses common misconceptions.","journal-title":"Pain Pract"},{"issue":"5","key":"732_CR7","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.clinthera.2010.04.018","volume":"32","author":"A Gordon","year":"2010","unstructured":"Gordon A, Callaghan D, Spink D, Cloutier C, Dzongowski P, O\u2019Mahony W, et al. Buprenorphine transdermal system in adults with chronic low back pain: a randomized, double-blind, placebo-controlled crossover study, followed by an open-label extension phase. Clin Ther Excerpta Medica Inc. 2010;32(5):844\u201360.","journal-title":"Clin Ther Excerpta Medica Inc"},{"issue":"1","key":"732_CR8","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/s12891-017-1664-4","volume":"18","author":"DH Yoon","year":"2017","unstructured":"Yoon DH, Bin S-I, Chan SK-C, Chung CK, In Y, Kim H, et al. Effectiveness and tolerability of transdermal buprenorphine patches: a multicenter, prospective, open-label study in Asian patients with moderate to severe chronic musculoskeletal pain. BMC Musculoskelet Disord. BMC Musculoskelet Disord. 2017;18(1):337.","journal-title":"BMC Musculoskelet Disord"},{"issue":"11","key":"732_CR9","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1097\/j.pain.0000000000000670","volume":"157","author":"J Gimbel","year":"2016","unstructured":"Gimbel J, Spierings ELH, Katz N, Xiang Q, Tzanis E, Finn A. Efficacy and tolerability of buccal buprenorphine in opioid-experienced patients with moderate to severe chronic low back pain: results of a phase 3, enriched enrollment, randomized withdrawal study. PainPain. 2016;157(11):2517\u201326.","journal-title":"PainPain"},{"key":"732_CR10","unstructured":"Reckitt Benckiser Pharmaceuticals. Buprenex (buprenorphine hydrochloride) injection, solution. 2007."},{"key":"732_CR11","doi-asserted-by":"crossref","unstructured":"Yarlas A, Miller K, Wen W, Lynch SY, Ripa SR, Pergolizzi J V, et al. Buprenorphine transdermal system improves sleep quality and reduces sleep disturbance in patients with moderate-to-severe chronic low Back pain\u00a0: results from two randomized controlled trials. Pain Pract 2015;541(Trial I).","DOI":"10.1111\/papr.12281"},{"issue":"5","key":"732_CR12","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/j.1533-2500.2010.00378.x","volume":"10","author":"J Pergolizzi","year":"2010","unstructured":"Pergolizzi J, Aloisi AM, Dahan A, Filitz J, Langford R, Likar R, et al. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract. 2010;10(5):428\u201350.","journal-title":"Pain Pract"},{"issue":"6","key":"732_CR13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.suponc.2012.05.002","volume":"10","author":"MP Davis","year":"2012","unstructured":"\u2022\u2022 Davis MP. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. J Support Oncol. 2012;10(6):209\u201319 An excellent review on the compelling safety and practical reasons to use buprenorphine as a first-line agent for treating pain.","journal-title":"J Support Oncol"},{"issue":"2","key":"732_CR14","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.clinthera.2015.12.016","volume":"38","author":"SA Bai","year":"2016","unstructured":"Bai SA, Xiang Q, Finn A. Evaluation of the pharmacokinetics of single- and multiple-dose buprenorphine buccal film in healthy volunteers. Clin Ther Elsevier. 2016;38(2):358\u201369.","journal-title":"Clin Ther Elsevier"},{"issue":"Suppl 1","key":"732_CR15","doi-asserted-by":"crossref","first-page":"s3","DOI":"10.1191\/0269216306pm1126oa","volume":"20","author":"A Dahan","year":"2006","unstructured":"Dahan A. Opioid-induced respiratory effects: new data on buprenorphine. Palliat MedPalliat Med. 2006;20(Suppl 1):s3\u20138.","journal-title":"Palliat MedPalliat Med"},{"issue":"18","key":"732_CR16","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.2165\/11208250-000000000-00000","volume":"71","author":"GL Plosker","year":"2011","unstructured":"Plosker GL. Buprenorphine 5, 10 and 20 mug\/h transdermal patch: a review of its use in the management of chronic non-malignant pain. DrugsDrugs. 2011;71(18):2491\u2013509.","journal-title":"DrugsDrugs"},{"issue":"1","key":"732_CR17","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s11095-007-9440-z","volume":"25","author":"Ashraf Yassen","year":"2007","unstructured":"Yassen A, Olofsen E, Kan J, Dahan A, Danhof M. Pharmacokinetic\u2013pharmacodynamic modeling of the effectiveness and safety of buprenorphine and fentanyl in rats. 2007;","journal-title":"Pharmaceutical Research"},{"issue":"6","key":"732_CR18","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/jcpt.12196","volume":"39","author":"RB Raffa","year":"2014","unstructured":"Raffa RB, Haidery M, Huang HM, Kalladeen K, Lockstein DE, Ono H, et al. The clinical analgesic efficacy of buprenorphine. J Clin Pharm TherJ Clin Pharm Ther. 2014;39(6):577\u201383.","journal-title":"J Clin Pharm TherJ Clin Pharm Ther"},{"key":"732_CR19","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1124\/jpet.113.209478","volume":"348","author":"DA Tompkins","year":"2014","unstructured":"Tompkins DA, Smith MT, Mintzer MZ, Campbell CM, Strain EC. A double blind, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphine s. J Pharmacol Exp Ther J Pharmacol Exp Ther. 2014;348:217\u201326.","journal-title":"J Pharmacol Exp Ther J Pharmacol Exp Ther"},{"issue":"1","key":"732_CR20","first-page":"E1","volume":"21","author":"AB Jonan","year":"2018","unstructured":"Jonan AB, Kaye AD, Urman RD. Buprenorphine formulations: clinical best practice strategies recommendations for perioperative management of patients undergoing surgical or interventional pain procedures. Pain physician3. 2018;21(1):E1\u201312.","journal-title":"Pain physician3"},{"key":"732_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2014.07.035","volume":"144","author":"MK Greenwald","year":"2014","unstructured":"Greenwald MK, Comer SD, Fiellin DA. Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy. Drug Alcohol DependDrug Alcohol Depend. 2014;144:1\u201311.","journal-title":"Drug Alcohol DependDrug Alcohol Depend"},{"key":"732_CR22","unstructured":"Endo Pharmaceuticals I. Belbuca prescribing information. 2015;"},{"key":"732_CR23","unstructured":"Purdue Pharma LP. Butrans prescribing Inform 2014;(5)."},{"issue":"1","key":"732_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/00325481.2016.1128307","volume":"128","author":"RL Rauck","year":"2016","unstructured":"\u2022 Rauck RL, Potts J, Xiang Q, Tzanis E, Finn A. Efficacy and tolerability of buccal buprenorphine in opioid-naive patients with moderate to severe chronic low back pain. Postgrad Med Taylor & Francis. 2016;128(1):1\u201311 A study that highlights the average therapeutic dose in opioid-na\u00efve patients for chronic low back pain.","journal-title":"Postgrad Med Taylor & Francis"},{"issue":"1","key":"732_CR25","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1080\/00325481.2017.1267537","volume":"129","author":"L Wallace","year":"2017","unstructured":"Wallace L, Kadakia A. Buprenorphine transdermal system utilization. Postgrad Med Taylor & Francis. 2017;129(1):81\u20136.","journal-title":"Postgrad Med Taylor & Francis"},{"issue":"9","key":"732_CR26","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.2337\/dc16-0123","volume":"39","author":"RW Simpson","year":"2016","unstructured":"Simpson RW, Wlodarczyk JH. Transdermal buprenorphine relieves neuropathic pain: a randomized, double-blind, parallel-group, placebo-controlled trial in diabetic peripheral neuropathic pain. Diabetes CareDiabetes Care. 2016;39(9):1493\u2013500.","journal-title":"Diabetes CareDiabetes Care"},{"issue":"3","key":"732_CR27","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/j.1360-0443.2006.01348.x","volume":"101","author":"SC Sigmon","year":"2006","unstructured":"Sigmon SC, Moody DE, Nuwayser ES, Bigelow GE. An injection depot formulation of buprenorphine: extended biodelivery and effects. AddictionAddiction. 2006;101(3):420\u201332.","journal-title":"AddictionAddiction"},{"key":"732_CR28","first-page":"CD009596","volume":"3","author":"M Schmidt-Hansen","year":"2015","unstructured":"Schmidt-Hansen M, Bromham N, Taubert M, Arnold S, Hilgart JS. Buprenorphine for treating cancer pain. Cochrane Database Syst RevCochrane Database Syst Rev. 2015;3:CD009596.","journal-title":"Cochrane Database Syst RevCochrane Database Syst Rev"}],"container-title":["Current Pain and Headache Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11916-018-0732-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-018-0732-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-018-0732-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T09:47:56Z","timestamp":1662198476000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11916-018-0732-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,5]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["732"],"URL":"https:\/\/doi.org\/10.1007\/s11916-018-0732-2","relation":{},"ISSN":["1531-3433","1534-3081"],"issn-type":[{"value":"1531-3433","type":"print"},{"value":"1534-3081","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,5]]},"assertion":[{"value":"5 October 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Fishman reports personal fees and sponsored research from Medtronic, Inc. and Biotronik, Inc. He reports personal fees from Nevro, Inc. and Depomed and sponsored research from Stimgenics, LLC, all of which are outside the submitted work. Dr. Kim reports that he is on the speaker bureau for Jazz and Collegium. He is also a consultant for Medtronic and Biotronik, and has done research for Medtronic, Stimgenics, and Vertiflex. Dr. Kim is on the medical board of CBsync and Agrokind.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"83"}}